open access
Brain-derived neurotrophic factor serum concentration and BDNF Val66Met polymorphism in patients with peripheral artery disease: the importance of heart failure
, 1, 3, 4, 4, 5, 12
Affiliations- Department of Clinical Neuropsychology, Nicolaus Copernicus University in Torun, Collegium Medicum in Bydgoszcz, Bydgoszcz, Poland
- Department of Cardiac Rehabilitation and Experimental Cardiology, Władysław Biegański’s Regional Specialist Hospital in Grudziadz, Poland
- Department of Forensic Medicine, Division of Molecular & Forensic Genetics, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Poland
- Department of Geriatrics, Nicolaus Copernicus University in Torun, L. Rydygier Collegium Medicum in Bydgoszcz
- Department of Vascular and Internal Diseases, Nicolaus Copernicus University in Torun, L. Rydygier Collegium Medicum in Bydgoszcz
open access
Abstract
Introduction: Brain-derived neurotrophic factor (BDNF) and BDNF Val66Met polymorphism have been associated with cardiovascular diseases such as atherosclerosis, congestive heart failure (CHF), hypertension and ischaemic heart disease (IHD). To the authors’ knowledge, such connections have not been described in peripheral artery disease (PAD) yet.
Material and methods: 159 PAD subjects and 57 controls were included. All enrolled subjects underwent evaluation of clinical status. Information on comorbidities such as diabetes type 2, hypertension, IHD and CHF, was gathered. Serum concentrations of BDNF were measured by ELISA. Genotypes of the BDNF-AS SNP rs6265 were determined using TaqMan SNP Genotyping Assay.
Results: PAD patients had significantly lower BDNF serum concentrations compared to controls (median values of 7.2 vs. 35.1 ng/mL, P < 0.001). Concentrations were significantly lower in patients with concomitant CHF (P < 0.05). The CHF subgroup was characterised by a greater prevalence of diabetes and ischaemic heart disease (P < 0.01). There was no significant difference between BDNF serum concentrations and other comorbidities, ABI, and medical history including disease duration and past interventions. No important correlations were found for BDNF Val66Met polymorphism.
Conclusions: The present study adds to the body of evidence associating BDNF and atherosclerosis. The serum BDNF concentrations were lower in PAD, especially in a subgroup with comorbid CHF. These results suggest that a larger cardiovascular burden is connected with decreased BDNF serum concentrations. No evidence was found to support the hypothesis that BDNF gene polymorphism may be a contributing factor in the pathogenesis of cardiovascular diseases such as PAD.
Abstract
Introduction: Brain-derived neurotrophic factor (BDNF) and BDNF Val66Met polymorphism have been associated with cardiovascular diseases such as atherosclerosis, congestive heart failure (CHF), hypertension and ischaemic heart disease (IHD). To the authors’ knowledge, such connections have not been described in peripheral artery disease (PAD) yet.
Material and methods: 159 PAD subjects and 57 controls were included. All enrolled subjects underwent evaluation of clinical status. Information on comorbidities such as diabetes type 2, hypertension, IHD and CHF, was gathered. Serum concentrations of BDNF were measured by ELISA. Genotypes of the BDNF-AS SNP rs6265 were determined using TaqMan SNP Genotyping Assay.
Results: PAD patients had significantly lower BDNF serum concentrations compared to controls (median values of 7.2 vs. 35.1 ng/mL, P < 0.001). Concentrations were significantly lower in patients with concomitant CHF (P < 0.05). The CHF subgroup was characterised by a greater prevalence of diabetes and ischaemic heart disease (P < 0.01). There was no significant difference between BDNF serum concentrations and other comorbidities, ABI, and medical history including disease duration and past interventions. No important correlations were found for BDNF Val66Met polymorphism.
Conclusions: The present study adds to the body of evidence associating BDNF and atherosclerosis. The serum BDNF concentrations were lower in PAD, especially in a subgroup with comorbid CHF. These results suggest that a larger cardiovascular burden is connected with decreased BDNF serum concentrations. No evidence was found to support the hypothesis that BDNF gene polymorphism may be a contributing factor in the pathogenesis of cardiovascular diseases such as PAD.
Keywords
Brain-derived neurotrophic factor, peripheral arterial disease, heart failure, atherosclerosis, Val66Met
About this articleTitle
Brain-derived neurotrophic factor serum concentration and BDNF Val66Met polymorphism in patients with peripheral artery disease: the importance of heart failure
Journal
Issue
Article type
Original article
Pages
203-207
Published online
2023-07-20
Page views
280
Article views/downloads
318
DOI
Bibliographic record
Medical Research Journal 2023;8(3):203-207.
Keywords
Brain-derived neurotrophic factor
peripheral arterial disease
heart failure
atherosclerosis
Val66Met
Authors
Aleksandra Chyrek-Tomaszewska
Alicja Katarzyna Popiołek
Katarzyna Linkowska
Mariusz Kozakiewicz
Adam Szelągowski
Jacek Budzyński
Maciej Kazimierz Bieliński
References (27)- Pytka MJ, Pałasz-Borkowska A, Tarchalski JL, et al. The serum concentration of brain‑derived neurotrophic factor is lower in ambulatory and clinically stable patients with more advanced systolic heart failure. Pol Arch Intern Med. 2022; 132(10).
- Berezin AE, Berezin AA, Lichtenauer M. Myokines and Heart Failure: Challenging Role in Adverse Cardiac Remodeling, Myopathy, and Clinical Outcomes. Dis Markers. 2021; 2021: 6644631.
- Chen Z, Zhang H. A meta-analysis on the role of brain-derived neurotrophic factor in Parkinson’s disease patients. Advances in Clinical and Experimental Medicine. 2022; 32(3): 285–295.
- Bathina S, Das UN. Brain-derived neurotrophic factor and its clinical implications. Arch Med Sci. 2015; 11(6): 1164–1178.
- Karantali E, Kazis D, Papavasileiou V, et al. Serum BDNF Levels in Acute Stroke: A Systematic Review and Meta-Analysis. Medicina (Kaunas). 2021; 57(3).
- Nowroozi A, Salehi MA, Mohammadi S. Brain-derived neurotrophic factor in patients with epilepsy: A systematic review and meta-analysis. Epilepsy Res. 2021; 178: 106794.
- Green MJ, Matheson SL, Shepherd A, et al. Brain-derived neurotrophic factor levels in schizophrenia: a systematic review with meta-analysis. Mol Psychiatry. 2011; 16(9): 960–972.
- Polyakova M, Stuke K, Schuemberg K, et al. BDNF as a biomarker for successful treatment of mood disorders: a systematic & quantitative meta-analysis. J Affect Disord. 2015; 174: 432–440.
- Brandys MK, Kas MJH, van Elburg AA, et al. A meta-analysis of circulating BDNF concentrations in anorexia nervosa. World J Biol Psychiatry. 2011; 12(6): 444–454.
- Ornell F, Hansen F, Schuch FB, et al. Brain-derived neurotrophic factor in substance use disorders: A systematic review and meta-analysis. Drug Alcohol Depend. 2018; 193: 91–103.
- Hao LS, Du Y, Chen L, et al. Brain-derived neurotrophic factor as a biomarker for obsessive-compulsive disorder: A meta-analysis. J Psychiatr Res. 2022; 151: 676–682.
- Davarpanah M, Shokri-Mashhadi N, Ziaei R, et al. A systematic review and meta-analysis of association between brain-derived neurotrophic factor and type 2 diabetes and glycemic profile. Sci Rep. 2021; 11(1): 13773.
- Shafi O. Switching of vascular cells towards atherogenesis, and other factors contributing to atherosclerosis: a systematic review. Thromb J. 2020; 18: 28.
- Barman HA, Şahin I, Atıcı A, et al. Prognostic significance of brain-derived neurotrophic factor levels in patients with heart failure and reduced left ventricular ejection fraction. Anatol J Cardiol. 2019; 22(6): 309–316.
- Jin H, Ji JJ, Zhu Yi, et al. Brain-Derived Neurotrophic Factor, a New Predictor of Coronary Artery Calcification. Clin Appl Thromb Hemost. 2021; 27: 1076029621989813.
- Sustar A, Perkovic MN, Erjavec GN, et al. Association between reduced brain-derived neurotrophic factor concentration & coronary heart disease. Indian J Med Res. 2019; 150(1): 43–49.
- Montone RA, Camilli M, Del Buono MG, et al. Brain-derived neurotrophic factor in patients with acute coronary syndrome. Transl Res. 2021; 231: 39–54.
- Aslan G, Polat V, Bozcali E, et al. Evaluation of serum platelet-derived growth factor receptor-ß and brain-derived neurotrophic factor levels in microvascular angina. Anatol J Cardiol. 2020; 24(6): 397–404.
- Bieliaski M, Lesiewska N, Jaracz M, et al. Brain-Derived Neurotrophic Factor Val66Met Polymorphism in Contex of Executive Functions and Working Memory in Obese Patients. Neuropsychiatry. 2018; 08(01).
- Sandrini L, Castiglioni L, Amadio P, et al. Impact of Val66Met Polymorphism on Myocardial Infarction: Exploring the Macrophage Phenotype. Cells. 2020; 9(5).
- Sampson UKA, Fowkes FGR, Naidoo NG, Criqui MH. Peripheral Artery Disease. . In: Prabhakaran D, Anand S, Gaziano TA, Mbanya JC, Nugent R. ed. Cardiovascular, Respiratory, and Related Disorders. 3rd ed. The International Bank for Reconstruction and Development/The World Bank, Washington (DC) 2017.
- PTD Z. Polskie Towarzystwo Diabetologiczne. 2017 Guidelines on the management of diabetic patients. A position of Diabetes Poland. Clinical Diabetology. 2017; 6(A): 1–80.
- Mancia G, Fagard R, Narkiewicz K, et al. Task Force Members. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013; 31(7): 1281–1357.
- Montalescot G, Sechtem U, Achenbach S, et al. Task Force Members, ESC Committee for Practice Guidelines, Document Reviewers. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013; 34(38): 2949–3003.
- Ponikowski P, Voors AA, Anker SD, et al. ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016; 37(27): 2129–2200.
- Trombetta IC, DeMoura JR, Alves CR, et al. Serum Levels of BDNF in Cardiovascular Protection and in Response to Exercise. Arq Bras Cardiol. 2020; 115(2): 263–269.
- Kadowaki S, Shishido T, Honda Y, et al. Additive clinical value of serum brain-derived neurotrophic factor for prediction of chronic heart failure outcome. Heart Vessels. 2016; 31(4): 535–544.